BC
DGX icon

Bridgefront Capital’s Quest Diagnostics DGX Stock Holding History

Bridgefront Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,456
Closed -$1.09M – 658
2025
Q1 		$1.09M Buy
+6,456
New +$1.06M 0.32% 69
2024
Q4 		– Sell
-2,063
Closed -$320K – 628
2024
Q3 		$320K Sell
2,063
-1,645
-44% -$246K 0.12% 297
2024
Q2 		$508K Buy
+3,708
New +$508K 0.21% 161
2023
Q4 		– Sell
-5,689
Closed -$693K – 417
2023
Q3 		$693K Buy
+5,689
New +$758K 0.49% 32
2022
Q3 		– Sell
-4,395
Closed -$584K – 345
2022
Q2 		$584K Buy
+4,395
New +$599K 0.65% 21
2021
Q1 		– Sell
-3,878
Closed -$462K – 731
2020
Q4 		$462K Buy
+3,878
New +$473K 0.16% 235

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bridgefront Capital's DGX Position: Q2 2025 in Review

Bridgefront Capital sold out of Quest Diagnostics (DGX) in Q2 2025, closing a stake of 6,456 shares — an estimated $1.09M sold.

Bridgefront Capital first reported a position in DGX in Q4 2020 and held it in 6 quarters. The position peaked at $1.09M in Q1 2025. 990 funds tracked by Wall St. Rank hold DGX as of Q2 2025.

  • Bridgefront Capital reported no remaining Quest Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Bridgefront Capital sold 6,456 Quest Diagnostics shares in Q2 2025, an estimated $1.09M.
  • Bridgefront Capital first reported a position in Quest Diagnostics in Q4 2020 and held it in 6 quarters.
  • Bridgefront Capital's Quest Diagnostics position peaked at $1.09M in Q1 2025.
  • 990 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2025.

Based on Bridgefront Capital's 13F filing for Q2 2025, filed 14 Aug 2025.